Citigroup’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-54,839
| Closed | -$4.13M | – | 6658 |
|
|
2022
Q2 | $4.13M | Buy |
54,839
+20,567
| +60% | +$914K | ﹤0.01% | 1650 |
|
|
2022
Q1 | $920K | Sell |
34,272
-79,131
| -70% | -$2.66M | ﹤0.01% | 3052 |
|
|
2021
Q4 | $5.41M | Buy |
113,403
+78,514
| +225% | +$3.51M | ﹤0.01% | 1769 |
|
|
2021
Q3 | $2.32M | Sell |
34,889
-25,972
| -43% | -$1.85M | ﹤0.01% | 2424 |
|
|
2021
Q2 | $4.75M | Buy |
60,861
+18,942
| +45% | +$1.4M | ﹤0.01% | 1935 |
|
|
2021
Q1 | $3.97M | Buy |
41,919
+15,390
| +58% | +$1.83M | ﹤0.01% | 1962 |
|
|
2020
Q4 | $3.23M | Buy |
26,529
+6,783
| +34% | +$743K | ﹤0.01% | 2413 |
|
|
2020
Q3 | $1.73M | Sell |
19,746
-14,751
| -43% | -$1.03M | ﹤0.01% | 2780 |
|
|
2020
Q2 | $2.23M | Buy |
34,497
+10,784
| +45% | +$622K | ﹤0.01% | 2694 |
|
|
2020
Q1 | $1.06M | Sell |
23,713
-3,420
| -13% | -$182K | ﹤0.01% | 3116 |
|
|
2019
Q4 | $1.69M | Buy |
27,133
+12,998
| +92% | +$618K | ﹤0.01% | 3179 |
|
|
2019
Q3 | $531K | Buy |
14,135
+12,283
| +663% | +$535K | ﹤0.01% | 4286 |
|
|
2019
Q2 | $75K | Buy |
+1,852
| New | +$66.1K | ﹤0.01% | 6137 |
|
Citigroup's TPTX Position: Q3 2022 in Review
Citigroup sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 54,839 shares — an estimated $4.13M sold.
Citigroup first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $5.41M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Citigroup reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Citigroup sold 54,839 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4.13M.
- Citigroup first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Citigroup's Turning Point Therapeutics, Inc. Common Stock position peaked at $5.41M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.